Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6007 USD | +1.81% | -15.39% | +68.26% |
05-08 | Transcript : IM Cannabis Corp., Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | IM Cannabis Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+68.26% | 8.33M | - | - | |
+15.43% | 3.45B | C- | ||
+107.45% | 1.95B | C | ||
+179.37% | 92.19M | - | - | |
+234.62% | 50.34M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- IMCC Stock
- IMCC Stock
- Ratings IM Cannabis Corp.